Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.83 |
| ▸ | HMGCR | P04035 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 3/20 | 0.41 |
| ▸ | CPT2 | P23786 | 2/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL10934305 | 1.00 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8107350 | 1.00 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7113923 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8758555 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL543587 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL156916 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL597226 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9728576 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8604353 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7113941 | 0.97 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12453698-B2 | Pharmaceutical biodissolvable gels for drug delivery | AIVIVA BIOPHARMA, INC. (US) | 2025-10-28 | — | — | US | claimed |
| US-20250262187-A1 | INJECTABLE FORMULATIONS | CYBIN UK LTD (GB) | 2025-08-21 | — | — | US | claimed |
| US-20250207170-A1 | CARBON CAPTURE IN TWO-STAGE FERMENTATION | LANZATECH, INC. | 2025-06-26 | — | — | US | claimed |
| EP-4438034-A2 | INJECTABLE FORMULATION | Cybin UK Ltd (GB) | 2024-10-02 | — | — | EP | claimed |
| EP-4138818-B1 | INJECTABLE FORMULATION | CYBIN UK LTD (GB) | 2024-08-21 | — | — | EP | claimed |
| WO-2023208974-A1 | A PRE-SCREENING METHOD AND A METHOD FOR SEPARATING ADENO-ASSOCIATED VIRUS CAPSIDS | CYTIVA BIOPROCESS R&D AB (SE) | 2023-11-02 | — | — | WO | claimed |
| CN-112430049-B | Curing agent for reducing permeability coefficient of heavy metal polluted soil and effective diffusion coefficient of pollutants as well as preparation method and application of curing agent | 东南大学 | 2022-06-07 | — | — | CN | claimed |
| US-20220008336-A1 | PHARMACEUTICAL BIODISSOLVABLE GELS FOR DRUG DELIVERY | AIVIVA BIOPHARMA, INC. | 2022-01-13 | — | — | US | claimed |
| EP-3886829-A1 | PHARMACEUTICAL BIODISSOLVABLE GELS FOR DRUG DELIVERY | AiViva Biopharma, Inc. (US) | 2021-10-06 | — | — | EP | claimed |
| CN-113242734-A | Pharmaceutical biosoluble gels for drug delivery | 艾葳生物科技有限公司 | 2021-08-10 | — | — | CN | claimed |
| US-5702880-A | AQUEOUS SOLUTION COMPRISING SPECIFIED CONCENTRATIONS OF POTASSIUM, SODIUM, MAGNESIUM, CALCIUM AND CHLORIDE IONS, HYDROXYETHYL STARCH, GLUCOSE, LACTATE BUFFER | BIOTIME, INC. (US) | 1997-12-30 | — | — | US | claimed |
| WO-1997043282-A2 | BENZOTHIAZOLINONES AS ANTI-ASTHMATIC AGENTS | KLINGE PHARMA GMBH (DE) | 1997-11-20 | — | — | WO | claimed |
| US-5674534-A | INCLUDES SALTING OUT SALT | ALKERMES, INC. (US) | 1997-10-07 | — | — | US | claimed |
| EP-0456782-B1 | TMB FORMULATION FOR SOLUBLE AND PRECIPITABLE HRP-ELISA | BIOVEST INC (US) | 1996-01-17 | — | — | EP | claimed |
| US-5211912-A | METHOD FOR DISINFECTING RED BLOOD CELLS, BLOOD PRODUCTS, AND CORNEAS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-05-18 | — | — | US | claimed |
| EP-0456782-A1 | TMB FORMULATION FOR SOLUBLE AND PRECIPITABLE HRP-ELISA. | TSI CORP (US) | 1991-11-21 | — | — | EP | claimed |
| WO-1991006672-A1 | TMB FORMULATION FOR SOLUBLE AND PRECIPITABLE HRP-ELISA | TSI-MASON RESEARCH INSTITUTE (US) | 1991-05-16 | — | — | WO | claimed |
| US-5013646-A | Tetramethylbenzidine, color, vinylpyrrolidone polymers and chromogen | TRANSGENIC SCIENCES, INC. (US) | 1991-05-07 | — | — | US | claimed |
| US-4950747-A | ADDING LOW MOLECULAR WEIGHT ELECTROLYTE BEFORE DRYING TO IMPROVE VISCOSITY | ALLIED COLLOIDS LTD. (GB) | 1990-08-21 | — | — | US | claimed |
| EP-0220514-B1 | COMPOSITION FOR INCREASING THE QUANTITY AND QUALITY OF FRUITS AND FLOWERS OF PLANTS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1990-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262187-A1 | INJECTABLE FORMULATIONS | SLC6A4, HTR5A, SLC6A3 | MEN1 125/4885ALDH1A1 2999/4885HMGCR 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.